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endothelin axis and apoptosis
Abstract
Endothelin axis (endothelin-1, -2 and -3, and endothelin receptors ETAR 
and ETBR) plays the key role in the various functions of the organism: acts 
as a modulator of vascular tone, tissue differentiation, growth and develop-
ment, cell proliferation, and hormone synthesis. In addition to its physiolog-
ical role, endothelin axis or individual components of the system, can have 
a significant effect on the tissue remodelling process and tumorigenesis. For 
example, endothelin-1 modulates mitosis, apoptosis and angiogenesis and 
can stimulate tumour invasion and metastasis. Increased endothelin-1 ex-
pression has been demonstrated in breast, ovarian, prostate and colorectal 
cancers. In tumour cells, the binding of endothelin-1 to ETA receptor in-
duces signalling pathway for survival. Endothelin-1 triggers the anti-apop-
totic signal through phosphatidylinositol 3-kinase (PI3-K)-dependent Akt 
phosphorylation. Endothelin receptors are coupled with G-proteins and they 
differ in sensitivity to antagonists. G-proteins are involved in cell signalling 
via adenylate cyclase, ion channels, PLC, PLA2, PKC, intracellular Ca2+, 
calcineurin and MAP kinase. It is believed that this activity is mediated by 
ETAR, since the application of their specific antagonist BQ-123 causes a 
reverse effect. Endothelin receptor antagonists such as A-127722, BQ-123, 
BQ-788, etc. act specifically on either proliferation or apoptosis depending 
on the cell type. Today, certain endothelin receptor antagonists, such as 
atrasentan, are applied in the treatment of lung and prostate cancer or are 
at different phases of clinical trials.
INTRoduCTIoN
Apoptosis is a genetically regulated process, which is defined both in time and in space, and plays a significant role in homeostasis during 
growth and development of the organism. Disturbances in the regula-
tion of programmed cell death may be the primary cause of various 
diseases including tumours, autoimmune diseases and various degen-
erative disorders.
Apoptosis was first described in 1972, as a type of cell death which 
leads to reduction of the cell volume, condensation and fragmentation 
of nuclei, swelling of the cell membrane and the loss of adhesive interac-
tion with neighbouring cells (1). Biochemical changes that occur in 
apoptosis include internucleosomal DNA fragmentation, expression of 
phosphatidylserine on the outer side of the plasma membrane and acti-
vated intracellular proteases (2, 3).
Tumour cells showed increased expression of specific proteins that 
prevent apoptosis and allow proliferation. Increased expression of anti-
apoptotic proteins can cause aggressive and rapid growth of tumour 
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tissue and resistance to anticancer drugs. Members of the 
Bcl-2 family proteins, members of the family of inhibitors 
of apoptosis (IAP), and heat shock proteins (HSP) are key 
factors that have been shown to contribute to the protec-
tion of tumour cells of spontaneous or induced apoptosis 
(4, 5, 6, 7, 8).
Over the past 20 years, numerous studies aimed at 
finding the ways of prevention and treatment of malignant 
disease. Several common characteristics of different types 
of tumours were found, which are: constant proliferation, 
insensitivity to growth control signals, opposing to cell 
death, secretion of proinflammatory molecules, resisting 
to immune rejection, unlimited duplication of DNA, in-
duction of angiogenesis, invasion into healthy tissue and 
metastasis, aerobic glycolysis, genome instability (9).
Endothelin axis (endothelin-1, -2 and -3, and endothe-
lin receptors ETAR and ETBR) plays the key role in the 
various functions of the organism: acts as a modulator of 
vascular tone, tissue differentiation, growth and develop-
ment, cell proliferation and hormone synthesis (10, 11). In 
addition to its physiological role, endothelin axis or indi-
vidual components of the system can have a significant 
effect on tissue remodelling and in the process of tumori-
genesis. Endothelin receptors act via G-proteins and acti-
vate specific signalling pathways. Binding of endothelin-1 
(ET-1) to ETA receptor tiggers signalling pathway for sur-
vival (12) in different tumour cells. ET-1 induces the anti-
apoptotic signal through phosphatidylinositol 3-kinase 
(PI3-K)-dependent Akt phosphorylation, depending on 
the time of exposure and the dose (13-15). On the other 
hand, the binding of ET-1 to ETB receptor enhances the 
clearance of circulating ET-1 and delays apoptosis. Endo-
thelin receptor antagonists such as atrasentan, Bq-123, 
Bq-788, etc. act on either proliferation or apoptosis de-
pending on the cell type (16-19). Certainly, endothelin 
receptor antagonists, such as atrasentan, zibotentan, yM-
598, bosentan, and macitentan are applied in the treat-
ment or are currently involved in different phases of 
clinical trials (20-24).
ENdoThElIN AXIS
Endothelins (ETs) are potent vasoconstricting peptides 
consisting of 21 amino acids. In 1988, yanagisawa and his 
colleagues isolated and purified this peptide from culti-
vated porcine vascular endothelial cells, and named it en-
dothelin (25). Cloning and sequence analysis of the endo-
thelin genes showed that ETs comprise the peptide family 
consisting of three isopeptides, namely ET-1, ET-2 and 
ET-3, and corresponding genes are located on chromo-
somes 6, 1 and 20 (26, 27). Each of the three ET isopep-
tides shows a high degree of sequence homology having the 
same aminoacides in 10 positions (2). ETs show similarities 
to sarafatoxin both in molecular structure and in biological 
activity. Sarafatoxin is a peptide that was isolated from 
snake venom Atractaspis engaddensis (28). Vasoactive intes-
tinal polypeptide (VIP) also shows structural similarity to 
ET. These vasoactive peptides are shown in Figure 1.
ET-1 is the strongest known vasoconstrictor. It con-
tains two disulfide bonds between Cys1- Cys15 and Cys3-
Cys11 in polypeptide molecules. Disulfide bonds contrib-
ute to the structural stability of the molecule. It is believed 
that these disulfide bonds are vital to high affinity binding 
Figure 1. Molecular structure of endothelin-1, -2, and -3, sarafatoxin and vasoactive intestinal polypeptide.
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to ETA receptor class, but they are less important in iden-
tifying ETB receptors class (11). Expression of ETs may 
be tissue-specific. In rats, the tissue amounts of ET-1 are 
generally higher than ET-3, except in the pituitary gland 
where ET-3 is higher, and in renal inner core where the 
concentration of these isopeptides is equal. ET-2 is preva-
lent only in the gastrointestinal tract. ETs are widely pres-
ent in mammals, and have been found in several species 
of fish and invertebrates, which suggests that ETs found 
in humans have a long evolutionary history (11). In hu-
mans, preproendothelin-1 consisting of 212 amino acids 
is synthesises first, and after proteolytical cleveage with 
dibasic pair-specific endopeptidase big ET-1 composed of 
38 amino acids is formed (10, 11, 26). Big ET-1, is trans-
formed into mature ET-1 (1-21) by the cleavage between 
Trp21-Val22, with the endothelin converting enzyme 
(ECE) or by chymase into ET-1 (1-31).
Vascular endothelial and other cells secrete ET-1 in 
response to various stimuli. According to in vitro studies, 
the release ET is stimulated by: haemodynamic stress, hy-
poxia, inflammatory cytokines (tumour necrosis factor, 
interleukin-1 and transforming growth factor-b), vasoac-
tive hormones (angiotensin II, vasopressin, bradykinin and 
adrenaline) and thrombin. Natriuretic peptide and hepa-
rin reduce the release of ET-1. It is assumed that ETs func-
tion as local hormones, and they act in autocrine, para-
crine and endocrine manner (11, 12, 26). Endothelial cells 
can rapidly adapt synthesis of ET-1 to the demand for 
regulation of vascular tone because of the short half-life of 
ET-1 (15-20 minutes for ET-1 mRNA, 4-7 minutes for 
ET-1 in plasma). An increased amount of ET-1 occurs 
after the binding of thrombin, angiotensin II and vaso-
pressin to the receptor. Therefore, through the cascades of 
secondary messengers, intracellular Ca2+ is increased and 
protein kinase C (PKC) is activated. Through AP-1 regu-
lation locus in the promotor region they stimulate tran-
scription of mRNA for ET-1. Creation of ET-1 mRNA is 
inhibited by nitric oxide (NO), prostacyclin and atrial na-
triuretic peptide, possibly via cGMP which inhibits phos-
phatidyl inositol mechanism. On the other hand, the 
synthesis of ET-1 is stimulated by thrombin, hypercholes-
terolemia, TGF b, bradykinin, epidermal growth factor, 
vasopressin, hypoxia, mechanical stress, cyclosporine, 
oxidized LDL, angiotensin II, Ca2+, etc. (12, 29-31).
To date, only two ET receptors, ETAR and ETBR, 
have been identified; however, a certain speculations on 
the existence of the ETC receptor also exists. The known 
ETB receptor subtypes are ETB1 and ETB2. ETA recep-
tor contains 427 amino acids and exhibits the highest af-
finity for ET-1 and the lowest for the ET-3. On the other 
hand, ETB receptor shows equal affinity for all three ETs. 
Both receptors are coupled with G-protein. Binding of ET 
to the appropriate receptor activates a number of signalling 
molecules, resulting in short-term or long-term changes in 
the target cells. Signalling pathways that mediate short-
term changes of cellular functions include: connection of 
receptor with G-proteins, phospholipase C (PLC), signal 
transduction via Ca2+, PKC, phospholipase A2 (PLA2), 
phospholipase D (PLD), Na+/H+ exchange and alkaliza-
tion of the cytoplasm and the creation of cAMP or cGMP, 
leading to vasoconstriction (11, 12, 31).
Hemodynamic changes characterized by changes in 
pressure and resistance to blood flow and hemodynamic 
control mechanisms involve neural, hormonal, renal, and 
local control. The vascular endothelium is considered to 
be a significant factor in local control, due to its anatom-
ic location between circulating blood and vascular smooth 
muscles. Under physiological conditions as well as after 
activation of the neurotransmitters, hormones, and under 
the influence of physical stimuli, different vasoactive sub-
stances are produced in endothelial cells. They act as: 1) 
vasoconstrictive factors: endothelins-1 (ET-1), cyclooxy-
genase pathway products, angiotensin II, 2) vasodilatation 
factors: NO, hyperpolarisation factor, prostacyclins and 
others. ET-1 acts through the ETAR located on the cell 
membranes of the smooth muscle of blood vessels, where-
in the activated PLC, raises the concentration of free in-
tracellular Ca2+ and causes vasoconstriction. The throm-
boxane A2 (TxA2), prostaglandin H2 (PGH2) and 
superoxide anion are the most significant vasoconstrictive 
factors which arise via cyclooxygenase pathway. Tx A2 
and PGH2 have a direct constrictive effect, while the su-
peroxide anion affects the inactivation of NO (31).
However, in addition to its physiological role endotelin 
axis or individual components of the system can have a 
significant effect in tissue remodelling but also in the pro-
cess of tumorogenesis. For example, endothelin-1 modu-
lates mitosis, apoptosis and angiogenesis and can stimulate 
tumour invasion and metastasis. Besides its vasocon-
striction action, ET-1 has mitogenic effect: it phosphory-
lates a number of cytoplasmic and membrane-associated 
proteins, participants in transmembrane signalling path-
ways that lead to cell proliferation. Signalling pathways 
that mediate long-term changes in cellular functions in-
clude the creation of several proto-oncogenes (c-fos, c-jun, 
c-myc, VF-30) and growth factors (PDGF, EGF, TGF-b, 
insulin), and co-mitogenic action. Different mitogenic 
stimuli activate an intracellular cascade of kinases, includ-
ing raf-1, mitogen-activated protein kinase, MAPK kinase 
and S6 kinase II, which carry messages from the cell 
membrane to the cell nucleus.
RolE of ENdoThElIN AXIS IN 
mAlIGNANT dISEASE
Numerous malignant tumours, including prostate, 
ovarian, colon, lung and breast cancer, are associated with 
the increased concentration of one or more of endothelin 
types and its receptors. Table 1 shows the role of endothe-
lin receptors in various tumours (12). The binding of ET-1 
to the receptors activates signalling pathways that trans-
mit mitogenic signals to the nucleus and promote cell 
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TAble 1
Role of ET receptors in different tumors (modified, according to Bagnato and Rosano 2008).
Endothelin receptors Receptor antagonists and their effects
Prostate cancer
(56, 57)
Expression of the ETAR increases with tumour stage 
and grade, and is associated with decreased ETBR 
expression.
ZD4054 inhibited ETA-receptor-mediated anti-
apoptotic events while allowing ETB-receptor-mediated 
pro-apoptotic signalling.
ETAR antagonist has demonstrated benefit in PSA 
progression, markers of bone turnover and pain.
ZD4054 has been associated with a promising improve-
ment in overall survival compared with placebo and 
was generally well tolerated in patients with metastatic 
hormone-resistant prostate cancer. 
Ovarian cancer
(58, 59, 60)
ETAR mRNA is present in 85% of primary and meta-
static cancers, and correlates with tumour grade. ETAR 
mediates all ET-1-induced tumour promoting effects.
ETAR and EGFR cross-talk enhances the metastatic 
potential of epithelial ovarian cancer. 
In preclinical studies ETAR antagonists display anti-
tumor effects and additive effects in combination with 
taxanes or gefitinib.
Blockade of ETAR and EGFR with zibosentan and 
gefitinib is a potential new therapeutic opportunity for 
epithelial ovarian cancer treatment.
Bladder cancer
(61)
Both ETAR and ETBR are expressed in bladder 
tumours. ETAR antagonist decreases lung metastases.
Melanoma
(62)
ETBR is over expressed and correlates with tumour 
progression. ETBR mediates all ET-1-induced  
tumour promoting effects.
ETBR antagonists inhibit melanoma cell growth 
in vitro and in vivo. The dual ETA/BR antagonist 
Bosentan has benefit in disease stabilization in  
metastatic melanoma patients.
Bone  
malignancies (63) ETAR is expressed in osteoblasts.
ETAR antagonist significantly reduced osteoblastic 
bone metastases and tumour burden in bone.
Breast cancer
(55)
ETAR expression correlates with several clinic- 
pathological parameters of aggressive carcinoma.
In preclinical studies ETAR antagonist inhibits tumour 
growth.
Renal cancer
(64) ETAR is expressed in different cell lines.
Head and neck 
cancer (65)
ET-1 is able to stimulate the proliferation of HNSCC 
cells via both, ETAR and ETBR.
Nasopharyngeal 
carcinoma (66) ETAR is over expressed in 74% of tumours.
ETAR antagonist inhibits tumour growth and  
metastasis and shows synergistic effects in combination 
with cytotoxic drugs.
Colon cancer
(67) Increased expression of ETAR and ETBR.
Dual ETA/BR antagonist Bosentan induces apoptosis  
or sensitises cells to Fas-induced apoptosis.
Cervical cancer
(68)
HPV-positive cervical carcinoma cells  
predominantly express functional ETAR.
ETAR antagonist inhibits tumor growth in  
monotherapy as well as in association with taxane.
Kaposi’s sarcoma
(69) Both ETAR and ETBR are expressed.




ETBR is expressed in cancer cells.
Endothelin B receptor antagonists block proliferation 
and induce apoptosis in glioma cells.
Dual ETA/BR antagonist induced apoptosis.
Bq788 and A192621 trigger apoptotic processes mainly 
via activation of the intrinsic mitochondrial pathway 
involving caspase-9 activation.
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proliferation. Those signalling pathways involve PLC (el-
evation of intracellular Ca, activation of PKC, activation 
of PI3-K and consequentially Akt pathway) and MAPKs; 
they are overlapping and partly synergistic. By applying 
ETAR and ETBR antagonists, the inhibition of growth 
is noticed only in the case of application of ETAR an-
tagonist and it is proved that ET-1 affects proliferation 
only through ETAR. Also, the mitogenic activity of ET-1 
is amplified by simultaneous application of growth factors 
such as EGF, bFGF, insulin, IGF, PDGF, TGF, IL-6 (12).
Endothelins are mitogenic for endothelial cells, smooth 
muscle vessels cells, fibroblasts and pericytes and, there-
fore, they act as activation of angiogenesis factors. Mito-
genesis of endothelial cells is mediated via ETRB and 
mitogenesis of smooth muscle cells and pericytes vessels 
through ETAR. ET-1 is included in all stages of neovas-
cularization, from proliferation to migration and tissue 
formation. Elevated levels of ET-1 are associated with in-
creased microvessel density and the expression of vascular 
endothelial growth factor (VEGF) in tumour cells, de-
pending on the dose and time, especially in a state of 
hypoxia (12). Increased expression of endothelin occurs 
during hypoxia by the action of transcription factor HIF-
1-b (hypoxia inducible factor-1b). More precisely, endo-
thelins stabilize HIF-1-b transcriptional complex that 
drives expression of angiogenic molecules such as VEGF 
and leads to cancer progression (33). During normal tis-
sue oxygenation, but even more so in the state of hypoxia, 
ET-1 increases the expression of cyclooxygenases COx-1 
and COx-2, and the formation of prostaglandin PGE2, 
which is, in addition to being a vasodilator, a possible 
regulator of tumour growth. Therefore, COx inhibitors 
reduce the creation of prostaglandin and VEGF, matrix 
metalloproteinases (MMPs) activation and invasiveness. 
Thus, HIF-1-b and COx are the downstream signalling 
molecules of the pathway that starts with ET-1 (12).
ET-1 is an anti-apoptotic factor. It can control signal-
ling pathways in the regulation of of cell survival, such as 
PI3K/Akt pathway. Addition of ET-1 inhibits apoptosis 
in tumour cells, induced by paclitaxel, by causing phos-
phorylation of the Bcl-2 family, depending on the con-
centration. ETAR antagonists block this effect. This 
means that ET-1 contributes to resistance to paclitaxel, 
acting through ETAR (34). Endothelin receptor antago-
nists, apart from affecting the reduction of tumour 
growth by inhibiting proliferation and inducing apopto-
sis, may contribute to eliminating the frequent occurrence 
of resistance to some conventional drugs such as pacli-
taxel, by increasing the sensitivity to the drug and induc-
ing apoptosis (33, 35, 36).
Acting via ETRA, ET-1 activates two families of pro-
teinases related to the process of metastasis, MMPs and 
urokinase type plasminogen activator (uPA) in tumour 
cells. Furthermore, ET-1 stimulates the FAK (focal adhe-
sion kinase) and phosphorylation of paxillin, which is an 
intracellular protein, the mediator in the interaction of 
the cytoskeleton and extracellular matrix (12).
Given that tumour vascularisation correlates with the 
expression of ET-1 in ovarian cancer and in colorectal 
tumours (37, 38) and brain tumours (39), additional tests 
were conducted and they showed that activation of ETAR 
by ET -1 stimulates production of VEGF. VEGF stimu-
lates tumour growth and angiogenesis by increasing levels 
of hypoxia-induced factor-1a (HIF-1a) (40). In normal 
oxygenation ET-1 activates signalling pathway sensitive 
to hypoxia, with the increase of concentration and / or 
reinforcement of stability of HIF-1a. HIF-1 transcription 
complex (HIF-1a/b), binds to the binding site to hypox-
ia sensitive element (HRE), causes an increased expression 
of genes and stimulates angiogenesis (15).
ENdoThElINS, ENdoThElIN 
RECEPToR ANTAGoNISTS ANd 
APoPToSIS
Apoptosis is a genetically controlled process of pro-
grammed cell death (1, 41). This process allows the tem-
porally and spatially predetermined removal of redundant 
or morphologically altered cells from the body, ensuring 
homeostasis. The mechanism of apoptosis is maintained 
by equilibrium between pro-apoptotic and anti-apoptotic 
factors (42). The process is necessary for the normal func-
tioning of the body, and a significant number of patho-
logical conditions associated with rapid or slow process of 
apoptosis.
Activators of apoptosis, through various intermediar-
ies, lead to activation of proteolytic caspase cascade. Ex-
tracellular activators may be hormones, growth factors, 
nitric oxide II (43), cytokines or toxins that bind to mem-
brane receptors or diffuse through the membrane. Intra-
cellular activators are released as a result of irreversible 
damage to DNA and other important cellular structures 
created under the influence of physical factors, hypoxia, 
aging, free radicals, increasing the concentration of Ca2+ 
ions and many other factors.
Most literature data confirms that ETs inhibit apopto-
sis. It was found that ET-1 acts as an anti-apoptotic factor 
in tumour cells. However, ET-1 shows the same effect in 
endothelial cells and vascular smooth muscle cells, which 
contributes to maintaining the integrity of newly formed 
blood vessels (44, 45).
In tumour cells, the binding of ET-1 to ETA receptor 
causes induced signalling pathway for survival. ET-1 trig-
gers the antiapoptotic signal through phosphatidylinositol 
3-kinase (PI3-K)- dependent Akt phosphorylation, de-
pending on the time of exposure and the dose (14, 34). 
On the other hand, the binding of ET-1 to ETB receptor 
enhances the clearance of circulating ET- 1 and delays 
apoptosis. Resistance to paclitaxel-mediated apoptosis 
caused by ET-1 (resistance) can be reversed by ETA recep-
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tor antagonists. In preclinical studies ETA receptor an-
tagonists cause 65% inhibition of tumour growth (46). 
Figure 2 shows the action of ET-1 through both endothe-
lin and death receptors. ET-1 acts as an anti-apoptotic 
factor by stabilizing the short arm of Fas ligand (FasL) 
inhibitory protein (FLIP) (47). Also, ET-1 can inhibit 
FasL-induced apoptosis by binding to high affinity sites 
(48). In human glioblastoma cells, blockade of ET sensi-
tizes cancer cells to FasL-mediated apoptosis (15, 49).
The pharmacological effect of ET can be explained by 
exogenous appliance of ET, but to clarify its physiological 
role, ET receptor antagonists are needed. So far, a large 
number of receptor antagonists, specific for ETA and ETB 
receptors, or both, have been synthesized and it allows for 
a better insight into the biological activity of ET in various 
tissues and their role in disease development (11, 31). 
Atrasentan is pharmacologically active enantiomer 
A-127722 (50). After oral application the bioavailability 
of ETAR antagonist, with prolonged exposure period, 
shows great affinity (the ETA receptor, Ki = 34 pM) and 
selectivity (1000 times greater selectivity for ETA than 
ETB receptors). Atrasentan blocks the signalling pathways 
involved in cancer cell proliferation and other processes 
that promote tumour growth (51). Significant results were 
reported in metastatic hormone-refractory prostate cancer 
treated with atrasentan, which in phase II clinical trials 
slowed tumour progression (52). The results of phase III 
clinical trials were omitted (53) as a promising reduction 
in tumour progression was not reflected in the overall sur-
vival benefit. Despite these results, atrasentan in combina-
tion with docetaxel may provide an alternative treatment 
option of this disease (54). ETA receptor antagonists show 
synergistic pro-apoptotic and anti-angiogenetic effect in 
combination with paclitaxel, leading to inhibition of tu-
mour growth by 90% to 40% of all tested cases (55).
CoNCluSIoN
Association between ET-1 and various types of cancer 
suggests a key role of ET-1 in the initiation or progression 
of tumours, defining endothelin axis as a potential thera-
peutic target. This fact has led to the development of sev-
eral approaches targeting endothelin axis in cancer ther-
apy. According to Rosano et al. (20), the potential 
advantage of dual ETRA and ETRB antagonists is that 
they can target not only cancer cell (which typically ex-
press ETRA) but also tumour-associated stromal ele-
ments, such as vascular, lymphatic and inflammatory cells 
and fibroblasts, which all express ETBR. ET-1 acts as 
tumour-stimulating anti-apoptotic factor by binding to 
high affinity sites of FasL or by stabilization of FLIP. ET-1 
also suppresses apoptosis via PI3-K/Akt pathway. On 
other hand, ETs lead to the stimulation of the new blood 
vessels. In addition to inhibition of the synthesis of ET-1 
or inhibition of ECE activity, the blocking of endothelin 
receptors represents the most promising approach in the 
field of control of multiple effects of ET-1, which are vital 
in creating a malignant phenotype.
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Figure 2. Endothelins, their receptors, antagonists of endothelin receptors, and signalling pathways. Figure modified from previous schemes 
(Tamkus 2009, Wang 2011).
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